Evidence to Support the Regulation Decision for the Usage of Pergolide in Patients with Parkinson’s Disease in Taiwan

被引：0

作者：

C. Gau

P. Lii

C. Hsu

机构：

[1] Center for Drug Evaluation,School of Pharmacy

[2] National Taiwan University,Graduate Institute of Clinical Pharmacy

[3] National Taiwan University,Department of Health

[4] Bureau of Pharmaceutical Affairs,undefined

来源：

Drug Safety | 2008年 / 31卷

关键词：

Levodopa; Dopamine Agonist; Valvular Heart Disease; Pergolide; Average Daily Dose;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：885 / 885

共 12 条

[1]

Schade R(2007)Dopamine agonists and the risk of cardiac-valve regurgitation New England Journal of Medicine 356 29-38

[2]

Andersohn F(2007)Valvular heart disease and the use of dopamine agonists for Parkinson’s disease New England Journal of Medicine 356 39-46

[3]

Suissa S(2006)Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study Neurology 67 1225-9

[4]

Zanettini R(2006)Valvular heart disease in Parkinson’s disease treated with ergot derivative dopamine agonists Movement Disorders 21 1261-4

[5]

Antonini A(undefined)undefined undefined undefined undefined-undefined

[6]

Gatto G(undefined)undefined undefined undefined undefined-undefined

[7]

Yamamoto M(undefined)undefined undefined undefined undefined-undefined

[8]

Uesugi T(undefined)undefined undefined undefined undefined-undefined

[9]

Nakayama T(undefined)undefined undefined undefined undefined-undefined

[10]

Kim J-Y(undefined)undefined undefined undefined undefined-undefined